AbbVie reports 60% reduction in progression risk for myeloma drug etentamig in Phase 3 trial

AbbVie announced results from a Phase 3 study of its T cell engager etentamig in patients with multiple myeloma.

The trial demonstrated a 60% relative reduction in the risk of disease progression or death compared with standard therapies.

The company said the data positions etentamig for potential entry into a crowded market and it will begin regulatory discussions.